| 摘要 |
<p>The present invention relates to crystalline salts of (S)-4-(3-[N-(2-[4-(5-carbamoyl-2-pyridyloxy)phenyl]-1,1-dimethylethyl)amino]-2-hydroxypropoxy)indole, a pharmaceutical formulation containing said salts, a process for preparing said salts, methods for treating obesity and Type II diabetes using said salt and to a method for agonizing the β3 receptor using said salts.</p> |
